# Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

> **NCT00927914** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 800 (actual)

## Conditions studied

- Mild to Moderate Diabetic Sensorimotor Polyneuropathy

## Interventions

- **DRUG:** Ranirestat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00927914
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-02
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927914, "Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00927914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*